• Posted by admin

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS CoV-2 Infection (COVID-19)

Investigators at Kaiser Permanente in Seattle WA Vaccines and Infectious Diseases are recruiting subjects age 18 to 55 years in a phase I, open-label, dose ranging clinical trial of the messenger ribonucleic acid (mRNA)-1273 vaccine that encodes the full-length prefusion stabilized spike (S) protein of severe acute respiratory syndrome (SARS)-CoV-2-virus infection, the cause of pandemic COVID-19.1 

Forty-five subjects enrolled into one of three cohorts will test the safety and reactions of a 2-dose vaccination schedule of mRNA-1273, given 28 days apart, across 3 dosages in healthy adults; and secondarily, the vaccine’s immunogenicity as measured by Immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) following a 2-dose vaccination schedule of mRNA-1273 at Day 57.   

If you are interested in participating in this trial contact: call: 206-287-2061 or email KPWA.vaccine@kp.org

Refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04283461